A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma-Reference-Cited by-同舟云学术

A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma

Published:2017-06 Issue:6 Volume:17 Page:347-353
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Maly Joseph J.,Christian Beth A.,Zhu Xiaohua,Wei Lai,Sexton Jennifer L.,Jaglowski Samantha M.,Devine Steven M.,Fehniger Todd A.,Wagner-Johnston Nina D.,Phelps Mitch A.,Bartlett Nancy L.,Blum Kristie A.

Funder

Comprehensive Cancer Center

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference23 articles.

1. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin lymphoma;Ansell;N Engl J Med,2015

2. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma;Gopal;Blood,2015

3. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial;Moskowitz;Lancet,2015

4. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells;Verhelle;Cancer Res,2007

5. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro;Dredge;Microvasc Res,2005

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted small molecule therapy and inhibitors for lymphoma;Future Medicinal Chemistry;2024-07-17

2. Population pharmacokinetics of lenalidomide in Chinese patients with influence of genetic polymorphisms of ABCB1;Scientific Reports;2024-01-31

3. Population pharmacokinetics of lenalidomide in Chinese patients with influence of genetic polymorphisms of ABCB1;2023-10-17

4. A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma;Haematologica;2023-09-14

5. Advances in the treatment of Hodgkin's lymphoma (Review);International Journal of Oncology;2023-04-04